Hepatic Thrombopoietin mRNA Is Increased in Acute Inflammation

Summary

The plasma concentration of thrombopoietin (TPO) in general is inversely related to the mass of platelets and megakaryocytes. However, reactive thrombocytosis of inflammatory disease is accompanied by elevated TPO levels. To investigate whether the rate of TPO mRNA expression is altered during acute inflammation, rats were injected with bacterial lipopolysaccharide (LPS). After 6 h, total RNA from liver and kidney was reverse transcribed and analyzed by competitive PCR for TPO and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). LPS-treated rats showed a significant increase in hepatic TPO mRNA concentration. The ratio of TPO to GAPDH mRNA was 3.5 ± 0.6% in the livers of control rats and 8.3 ± 2.0% in the livers of LPS-treated rats (mean ± SD). Thus, reactive thrombocytosis of inflammatory disease might result from an increase in hepatic TPO production. Since platelets are involved in the immune reaction, reactive thrombocytosis may be a mechanism of host defense.

Keywords

Thrombopoietin - inflammation - reactive thrombocytosis - acute phase reaction - LPS

• References

• 1 Eaton DL, de Sauvage FJ. Thrombopoietin: the primary regulator of megakaryocytopoiesis and thrombopoiesis. Exp Hematol 1997; 25: 1-7.
• 2 Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997; 89: 101-7.
• 3 Gurney AL, Kuang WJ, Xie MH, Malloy BE, Eaton DL, de Sauvage FJ. Genomic structure, chromosomal localization, and conserved alternative splice forms of thrombopoietin. Blood 1995; 85: 981-8.
• 4 Nagata Y, Shozaki Y, Nagahisa H, Nagasawa T, Abe T, Todokoro K. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost 1997; 77: 808-14.
• 5 Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, de Sauvage FJ. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154-61.
• 6 Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995; 85: 2720-30.
• 7 Cerutti A, Custodi P, Duranti M, Noris P, Balduini CL. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol 1997; 99: 281-4.
• 8 Heits F, Katschinski DM, Wilmsen U, Wiedemann GJ, Jelkmann W. Serum thrombopoietin and interleukin 6 concentrations in tumour patients and response to chemotherapy-induced thrombocytopenia. Eur J Haematol 1997; 59: 53-8.
• 9 Hsu HC, Tsai WH, Jiang ML, Ho CH, Hsu ML, Ho CK, Wang SY. Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. J Lab Clin Med 1999; 134: 392-7.
• 10 Wolber E-M, Jelkmann W. Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J Interferon Cytokine Res 2000; 20: 499-506.
• 11 Folman CC, Ooms M, Kuenen B, de Jong SM, Vet RJWM, De Haas M, von dem Borne AE. The role of thrombopoietin in post-operative thrombocytosis. Br J Haematol 2001; 114: 126-33.
• 12 Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-36.
• 13 Frede S, Fandrey J, Pagel H, Hellwig T, Jelkmann W. Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats. Am J Physiol 1997; 273: R1067-R1071.
• 14 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
• 15 Wolber E-M, Dame C, Fahnenstich H, Hofmann D, Bartmann P, Jelkmann W, Fandrey J. Expression of the thrombopoietin gene in human fetal and neonatal tissues. Blood 1999; 94: 97-105.
• 16 Wolber E-M, Ganschow R, Burdelski M, Jelkmann W. Hepatic thrombopoietin mRNA levels in acute and chronic liver failure of childhood. Hepatology 1999; 29: 1739-42.
• 17 Ogami K, Shimada Y, Sohma Y, Akahori H, Kato T, Kawamura K, Miyazaki H. The sequence of a rat cDNA encoding thrombopoietin. Gene 1995; 158: 309-10.
• 18 Peck-Radosavljevic M, Zacherl J, Meng YG, Pidlich J, Lipinski E, Langle F, Steininger R, Muhlbacher F, Gangl A. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?. J Hepatol 1997; 27: 127-31.
• 19 Peck-Radosavljevic M, Wichlas M, Pidlich J, Sims P, Meng G, Zacherl J, Garg S, Datz C, Gangl A, Ferenci P. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28: 1424-9.
• 20 Hino M, Nishizawa Y, Tagawa S, Yamane T, Morii H, Tatsumi N. Constitutive expression of the thrombopoietin gene in a human hepatoma cell line. Biochem Biophys Res Commun 1995; 217: 475-81.
• 21 Yamashita K, Matsuoka H, Ochiai T, Matsushita R, Kubuki Y, Suzuki M, Tsubouchi H. Hepatocyte growth factor/scatter factor enhances the thrombopoietin mRNA expression in rat hepatocytes and cirrhotic rat livers. J Gastroenterol Hepatol 2000; 15: 83-90.
• 22 Ishikawa T, Ichida T, Matsuda Y, Sugitani S, Sugiyama M, Kato T, Miyazaki H, Asakura H. Expression of hepatic thrombopoietin mRNA in primary cultured hepatocytes and in rats with acute liver injury or bone marrow suppression with or without cirhosis. J Gastroenterol Hepatol 2000; 15: 647-53.
• 23 Qian S, Fu F, Li W, Chen Q, de Sauvage FJ. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood 1998; 92: 2189-91.
• 24 Cerutti A, Custodi P, Duranti M, Cazzola M, Balduini CL. Circulating thrombopoietin in reactive conditions behaves like an acute phase reactant. Clin Lab Haematol 1999; 21: 271-5.
• 25 Ulich TR, Guo KZ, Remick D, del Castillo J, Yin SM. Endotoxin-induced cytokine gene expression in vivo. III. IL-6 mRNA and serum protein expression and the in vivo hematologic effects of IL-6. J Immunol 1991; 146: 2316-23.
• 26 Stohlawetz P, Folman CC, von dem Borne AE, Pernerstorfer T, Eichler HG, Panzer S, Jilma B. Effects of endotoxemia on thrombopoiesis in men. Thromb Haemost 1999; 81: 613-7.
• 27 de la Cadena RA, Majluf-Cruz A, Stadnicki A, Tropea M, Reda D, Agosti JM, Colman RW, Suffredini AF. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb Haemost 1998; 80: 114-8.
• 28 Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis 1997; 25: 951-68.
• 29 Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Müller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
• 30 Oda A, Miyakawa Y, Druker BJ, Ozaki K, Ohashi H, Kato T, Miyazaki H, Handa M, Ikebuchi K, Ikeda Y. Thrombopoietin-induced signal transduction and potentiation of platelet activation. Thromb Haemost 1999; 82: 377-84.
• 31 Folman CC, Linthorst GE, Van Mourik J, Van Willigen G, De Jonge E, Levi M, De Haas M, von dem Borne AE. Platelets release thrombopoietin (TPO) upon activation: another regulatory loop in thrombocytopoiesis?. Thromb Haemost 2000; 83: 923-30.